Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage driver-negative non-small-cell lung cancer (NSCLC), although most patients will ultimately have disease progression on these agents and the most effective treatment approach in this scenario remains uncertain. In this Review, the authors describe the outcomes in patients receiving second-line therapy for advanced-stage NSCLC and provide an overview of emerging therapies and future areas of research in this challenging clinical setting.
- Martin Reck
- Nikolaj Frost
- Fabrice Barlesi